Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers

Early-stage NSCLC Panel - a therapy selection panel providing a comprehensive overview of biomarkers for detecting early-stage lung cancer

FT. MYERS, FL / ACCESSWIRE / October 24, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today the commercial availability of two new tests, expanding its cancer portfolio of innovative products. These include Neo Comprehensive™ - Heme Cancers, a next-generation sequencing (NGS) panel with a comprehensive genomic profile of hematologic malignancies, and Early-stage Non-Small Cell Lung Cancer (NSCLC) Panel, a therapy selection panel designed specifically for early-stage NSCLC patients.

"With our newest panels, we can provide oncologists with the vital information they need to personalize cancer care, putting their patients on a path towards better outcomes right from the start of their cancer journey," said Warren Stone, President of Clinical Services at NeoGenomics. "Research shows that the selection of therapy informed by biomarker testing can be critical to improving patient outcomes. The commercial availability of these new panels highlights our mission to save lives by improving patient care, using biomarker testing paired with our uncompromising quality and exceptional service," Stone continued.

Neo Comprehensive - Heme Cancers is NeoGenomics' largest, most comprehensive heme NGS panel with broad coverage of genes associated with hematologic cancers. It further enhances NeoGenomics' extensive test menu for heme testing, especially the NGS portfolio, strengthening the company's position as a leading laboratory in heme oncology services.

The Early-stage NSCLC Panel is NeoGenomics' most focused early-stage lung cancer panel to date, detecting genomic alterations and gene expression in key biomarkers that are relevant in diagnosis, therapy selection, prognosis, and clinical trials. The Panel provides new, easy-to-interpret reports and a 7 day turn-around time, offering clinicians the ability to easily order the evidence-based set of concise, targeted, and actionable markers in a specific panel to support the management of their patients with lung cancer, at earlier stages of diagnosis.

About Neo Comprehensive™ - Heme Cancers

Neo Comprehensive - Heme Cancers is a comprehensive genomic profile (CGP) analyzing 433 genes relevant to most forms of hematologic malignancies from myeloid and lymphoid lineages, detecting SNVs (single nucleotide variants), InDels (insertions and deletions), CNVs (copy number variants), and fusions utilizing DNA and RNA NGS methods. This panel is aligned with the latest guidelines and the WHO 5^th Edition Classification of Haematolymphoid Tumours. It can provide key diagnostic information, including critical molecular determinations affecting therapeutic approaches, aid in risk stratification, predicting prognosis, and can be used in clinical research.

About Early-stage NSCLC Panel

The Early-stage NSCLC Panel is NeoGenomics' most focused early-stage lung cancer panel that detects genomic alterations and gene expression in key biomarkers that we believe are most relevant in diagnosis, therapy selection, prognosis, and clinical trials. The panel includes EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS (reactive oxygen species) and PD-L1 (programmed death-ligand 1) reported in a streamlined test report format.

The Early-stage NSCLC Panel is available as an enhancement of existing single-gene tests by simplifying ordering and increasing standardization of evidence-based multi-biomarker testing. Combining information about genetic alterations and PD-L1 expression provides the complete picture for targeted therapy decisions that provide the best outcomes for patients.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that together with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to applicable data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.

Forward Looking Statements

This press release includes forward-looking statements. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 23, 2023 as well as other information previously filed with the SEC. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements.

For further information, please contact:

NeoGenomics, Inc.
Kendra Sweeney
Vice President, Investor Relations and ESG
Kendra.sweeney@neogenomics.com
T: +1-239-877-7474

SOURCE: NeoGenomics, Inc.